3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
77
Breast Neoplasms
46
Colorectal Neoplasms
42
Neoplasms
41
Neoplasm Metastasis
34
Melanoma
31
Multiple Myeloma
30
Prostatic Neoplasms
29
Recurrence
28
Stomach Neoplasms
27
Pancreatic Neoplasms
27
Squamous Cell Carcinoma of Head and Neck
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Lung Neoplasms
26
Carcinoma, Renal Cell
25
Ovarian Neoplasms
23
Lymphoma, Large B-Cell, Diffuse
22
Leukemia, Myeloid, Acute
22
Triple Negative Breast Neoplasms
21
Lymphoma, Non-Hodgkin
21
Lymphoma, Follicular
21
Leukemia, Lymphocytic, Chronic, B-Cell
19
Glioblastoma
19
Myelodysplastic Syndromes
17
Uterine Cervical Neoplasms
16
Lymphoma
16
Colonic Neoplasms
15
Carcinoma, Transitional Cell
15
Lymphoma, Mantle-Cell
14
Leukemia
14
Interventions
Taxes
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Active not recruiting
×
Pancreatic Ductal Adenocarcinoma
×
Clear all
NCT04827953
2024-12-30
NUMANTIA
Nelum Corp
Phase 1/2
Active not recruiting
28 enrolled